Comparative Pharmacology
Head-to-head clinical analysis: CLINDAMYCIN PALMITATE HYDROCHLORIDE versus LINCOMYCIN HCL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLINDAMYCIN PALMITATE HYDROCHLORIDE versus LINCOMYCIN HCL.
CLINDAMYCIN PALMITATE HYDROCHLORIDE vs LINCOMYCIN HCL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Clindamycin palmitate hydrochloride is a prodrug that is hydrolyzed in vivo to clindamycin. Clindamycin binds to the 50S subunit of the bacterial ribosome and inhibits protein synthesis by blocking peptide bond formation. It also inhibits the early stages of protein synthesis by interfering with the initiation complex.
Lincomycin inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, inhibiting peptide bond formation and translocation.
150-300 mg orally every 6 hours. Maximum dose: 1.8 g/day.
600 mg IM every 12-24 hours or 600 mg IV every 8-12 hours, up to 8 g/day for severe infections.
None Documented
None Documented
Terminal elimination half-life is approximately 2.4–3.0 hours in adults with normal renal and hepatic function. In patients with severe hepatic impairment, half-life may be prolonged up to 8–10 hours.
4-5 hours (prolonged in renal impairment, up to 10 hours in anuria; no significant change in hepatic disease).
Approximately 10% of the dose is excreted unchanged in urine; the remainder is eliminated as inactive metabolites via bile (about 30–40%) and feces (about 50–60%). Renal clearance is minor and dosing adjustment is not typically required in renal impairment.
Renal (approximately 40% unchanged in urine) and biliary/fecal (approximately 50% as active drug and metabolites).
Category A/B
Category C
Lincosamide Antibiotic
Lincosamide Antibiotic